troglitazone has been researched along with Autoimmune Diabetes in 15 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Therapy was directed primarily at decreasing insulin resistance and thereby improving glucose intolerance by the administration of troglitazone, which increases insulin sensitivity." | 7.70 | Troglitazone ameliorates insulin resistance in a diabetic patient with Prader-Willi syndrome. ( Fujii, S; Fujita, K; Ishii, T; Kurimasa, H; Mori, T; Sato, T; Tanaka, S; Yamakita, T; Yoshioka, K, 1998) |
| "Thus, the prevention of autoimmune diabetes in NOD mice by TGZ seems to be associated with suppression of IL-1beta-induced ICAM-1 expression leading to a reduced vulnerability of pancreatic beta-cells during the effector stage of beta-cell destruction." | 5.32 | Prevention of autoimmune diabetes in NOD mice by troglitazone is associated with modulation of ICAM-1 expression on pancreatic islet cells and IFN-gamma expression in splenic T cells. ( Augstein, P; Berg, S; Dunger, A; Hehmke, B; Heinke, P; Salzsieder, E; Wachlin, G, 2003) |
| "Troglitazone has been reported to be beneficial in a small group of patients with nonalcoholic steatohepatitis (NASH)." | 5.31 | Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus. ( Angulo, P; Lindor, KD, 2001) |
| " Therapy was directed primarily at decreasing insulin resistance and thereby improving glucose intolerance by the administration of troglitazone, which increases insulin sensitivity." | 3.70 | Troglitazone ameliorates insulin resistance in a diabetic patient with Prader-Willi syndrome. ( Fujii, S; Fujita, K; Ishii, T; Kurimasa, H; Mori, T; Sato, T; Tanaka, S; Yamakita, T; Yoshioka, K, 1998) |
| "Troglitazone treatment of type 2 diabetic patients diminishes sCD40L levels, suggesting a novel antiinflammatory mechanism for limiting diabetes-associated arterial disease." | 2.71 | Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. ( Bernal, MR; Calle-Pascual, AL; Fernández-Cruz, A; Goldfine, A; Horton, E; Jarolim, P; Libby, P; Nuzzo, R; Schönbeck, U; Varo, JJ; Varo, N; Veves, A; Vicent, D, 2003) |
| "Thus, the prevention of autoimmune diabetes in NOD mice by TGZ seems to be associated with suppression of IL-1beta-induced ICAM-1 expression leading to a reduced vulnerability of pancreatic beta-cells during the effector stage of beta-cell destruction." | 1.32 | Prevention of autoimmune diabetes in NOD mice by troglitazone is associated with modulation of ICAM-1 expression on pancreatic islet cells and IFN-gamma expression in splenic T cells. ( Augstein, P; Berg, S; Dunger, A; Hehmke, B; Heinke, P; Salzsieder, E; Wachlin, G, 2003) |
| "Troglitazone has been reported to be beneficial in a small group of patients with nonalcoholic steatohepatitis (NASH)." | 1.31 | Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus. ( Angulo, P; Lindor, KD, 2001) |
| "Dyslipoproteinemia associated with type 2 diabetes comprises hypertriglyceridemia caused by reduced insulin sensitivity, and consequently, low HDL levels and an increase in the proportion of small dense LDL particles." | 1.31 | [Diabetic dyslipoproteinemia: physiopathological bases and treatment prospects]. ( Demant, T, 2001) |
| "Troglitazone is a new oral antidiabetic agent and has been reported to reduce insulin resistance and improve peripheral hyperinsulinemia in patients with noninsulin-dependent diabetes mellitus." | 1.30 | Effect of troglitazone on blood insulin levels after pancreas transplantation with systemic venous drainage in rats. ( Mitsuo, M; Nakai, I; Oka, T; Shimizu, Y; Uchiyama, K; Yasunami, Y, 1997) |
| "Troglitazone has recently been introduced in the treatment of Type 2 diabetes." | 1.30 | Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse. ( Batchelor, K; Beales, PE; Giorgini, AE; Liddi, R; Pozzilli, P; Procaccini, E; Signore, A, 1998) |
| "Troglitazone treatment with MLDSTZ injection prevented hyperglycemia (230 +/- 30 mg/dl) and, suppressed insulitis and TNF alpha production from intraperitoneal exudate cells." | 1.30 | Troglitazone can prevent development of type 1 diabetes induced by multiple low-dose streptozotocin in mice. ( Fujiwara, T; Fukushige, J; Horikoshi, H; Hosokawa, T; Izumi, T; Kurakata, S; Ogawa, J; Takahashi, S, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (53.33) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Solignac, M | 1 |
| Augstein, P | 1 |
| Dunger, A | 1 |
| Heinke, P | 1 |
| Wachlin, G | 1 |
| Berg, S | 1 |
| Hehmke, B | 1 |
| Salzsieder, E | 1 |
| Varo, N | 1 |
| Vicent, D | 1 |
| Libby, P | 1 |
| Nuzzo, R | 1 |
| Calle-Pascual, AL | 1 |
| Bernal, MR | 1 |
| Fernández-Cruz, A | 1 |
| Veves, A | 1 |
| Jarolim, P | 1 |
| Varo, JJ | 1 |
| Goldfine, A | 1 |
| Horton, E | 1 |
| Schönbeck, U | 1 |
| Lindsey, C | 1 |
| Graham, M | 1 |
| McMurphy, J | 1 |
| Shimabukuro, M | 1 |
| Koyama, K | 1 |
| Lee, Y | 1 |
| Unger, RH | 1 |
| Uchiyama, K | 1 |
| Nakai, I | 1 |
| Shimizu, Y | 1 |
| Mitsuo, M | 1 |
| Yasunami, Y | 1 |
| Oka, T | 1 |
| Gitlin, N | 1 |
| Julie, NL | 1 |
| Spurr, CL | 1 |
| Lim, KN | 1 |
| Juarbe, HM | 1 |
| Beales, PE | 1 |
| Liddi, R | 1 |
| Giorgini, AE | 1 |
| Signore, A | 1 |
| Procaccini, E | 1 |
| Batchelor, K | 1 |
| Pozzilli, P | 1 |
| Park, MH | 1 |
| Pelegrin, D | 1 |
| Haug, MT | 1 |
| Young, JB | 1 |
| Yamakita, T | 1 |
| Ishii, T | 1 |
| Mori, T | 1 |
| Yoshioka, K | 1 |
| Sato, T | 1 |
| Tanaka, S | 1 |
| Kurimasa, H | 1 |
| Fujita, K | 1 |
| Fujii, S | 1 |
| Herrine, SK | 1 |
| Choudhary, C | 1 |
| Ogawa, J | 1 |
| Takahashi, S | 1 |
| Fujiwara, T | 1 |
| Fukushige, J | 1 |
| Hosokawa, T | 1 |
| Izumi, T | 1 |
| Kurakata, S | 1 |
| Horikoshi, H | 1 |
| Isshiki, K | 1 |
| Haneda, M | 1 |
| Koya, D | 1 |
| Kikkawa, R | 1 |
| Angulo, P | 1 |
| Lindor, KD | 1 |
| Demant, T | 1 |
1 review available for troglitazone and Autoimmune Diabetes
| Article | Year |
|---|---|
[Kidney disease and insulin resistance--clinical impact of thiazolidinedione compounds for kidney disease].
Topics: Animals; Chromans; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents | 2000 |
1 trial available for troglitazone and Autoimmune Diabetes
| Article | Year |
|---|---|
Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones.
Topics: Acute Disease; Adult; Aged; Arteriosclerosis; Body Mass Index; CD40 Ligand; Chromans; Chronic Diseas | 2003 |
13 other studies available for troglitazone and Autoimmune Diabetes
| Article | Year |
|---|---|
[News on diabetes and public health perspectives].
Topics: Administration, Oral; Adult; Chromans; Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitu | 2002 |
Prevention of autoimmune diabetes in NOD mice by troglitazone is associated with modulation of ICAM-1 expression on pancreatic islet cells and IFN-gamma expression in splenic T cells.
Topics: Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Chromans; Cytokine | 2003 |
A retrospective review of thiazolidinediones with development of a troglitazone conversion protocol.
Topics: Aged; Alanine Transaminase; Chromans; Clinical Protocols; Contraindications; Diabetes Mellitus, Type | 2003 |
Leptin- or troglitazone-induced lipopenia protects islets from interleukin 1beta cytotoxicity.
Topics: Animals; Cell Survival; Cells, Cultured; Chromans; Diabetes Mellitus, Type 1; Fatty Acids, Nonesteri | 1997 |
Effect of troglitazone on blood insulin levels after pancreas transplantation with systemic venous drainage in rats.
Topics: Animals; Blood Glucose; Body Weight; Chromans; Diabetes Mellitus, Type 1; Drainage; Glucose Toleranc | 1997 |
Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone.
Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 1; Diabetes M | 1998 |
Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse.
Topics: Age Factors; Animals; Chromans; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 1; Fem | 1998 |
Troglitazone, a new antidiabetic agent, decreases cyclosporine level.
Topics: Aged; Chromans; Cyclosporine; Diabetes Mellitus, Type 1; Drug Interactions; Heart Transplantation; H | 1998 |
Troglitazone ameliorates insulin resistance in a diabetic patient with Prader-Willi syndrome.
Topics: Adolescent; Blood Glucose; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 1; Glucose Intoleran | 1998 |
Severe hepatotoxicity associated with troglitazone.
Topics: Cholestasis; Chromans; Diabetes Mellitus, Type 1; Fatal Outcome; Female; Humans; Hypoglycemic Agents | 1999 |
Troglitazone can prevent development of type 1 diabetes induced by multiple low-dose streptozotocin in mice.
Topics: Animals; Blood Glucose; Chromans; Cricetinae; Diabetes Mellitus, Experimental; Diabetes Mellitus, Ty | 1999 |
Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus.
Topics: Adult; Chemical and Drug Induced Liver Injury; Cholestasis; Chromans; Diabetes Mellitus, Type 1; Fat | 2001 |
[Diabetic dyslipoproteinemia: physiopathological bases and treatment prospects].
Topics: Anticholesteremic Agents; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Chromans; Clinical Tria | 2001 |